Abstract
Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 324-336 |
| Number of pages | 13 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 9 |
| Issue number | 3 |
| State | Published - Mar 1 2008 |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery